Literature DB >> 18249061

MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia.

Maria M Ho1, Donna E Hogge, Victor Ling.   

Abstract

OBJECTIVE: Overexpression of members of the adenosine triphosphate binding cassette (ABC) transporter superfamily has been implicated in multidrug resistance in cancer, but results in acute myeloid leukemia (AML) have been inconsistent. We investigated the expression and activity of ABC transporters in patient total blasts and subpopulations along the leukemic stem cell hierarchy.
MATERIALS AND METHODS: Using quantitative reverse transcriptase polymerase chain reaction, we measured expression of the ABC transporter superfamily in the blast cells from AML patients prior to chemotherapy. In addition, we measured ex vivo daunorubicin resistance of subpopulations with or without ABC inhibitors.
RESULTS: In the total blasts, no consistent difference was observed in 18 patients achieving complete remission (CR) and 13 patients who were refractory to induction chemotherapy (NR). However, among the subpopulation of CD34(+)CD38(-) AML cells (candidate "leukemic stem cells"), elevated expression of MDR1 and/or BCRP1, two ABC transporters associated with drug resistance, was found in 8 of 10 NR patients as compared to 0 of 7 CR patients. No such association was observed in the more differentiated CD34(+)CD38(+) or CD34(-) subpopulations. There was no significant difference in MRP1 expression between CR and NR patient samples in any of the subpopulations examined. The increased expression of MDR1 and BCRP1 in leukemic cells correlated with increased cellular daunorubicin resistance, which could be reversed by the ABC transporter inhibitors verapamil and PSC-833.
CONCLUSION: Expression of MDR1 and BCRP1 in leukemic stem cells correlates with chemotherapy response both at the cellular level and in AML patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18249061     DOI: 10.1016/j.exphem.2007.11.014

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  20 in total

1.  The efficient generation of immunocompetent dendritic cells from leukemic blasts in acute myeloid leukemia: a local experience.

Authors:  Kambiz Bagheri; Kamran Alimoghadam; Ali Akbar Pourfathollah; Zuhair Muhammad Hassan; Jamshid Hajati; Seyyed Mohammad Moazzeni
Journal:  Pathol Oncol Res       Date:  2008-09-20       Impact factor: 3.201

Review 2.  Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

Authors:  Karthika Natarajan; Yi Xie; Maria R Baer; Douglas D Ross
Journal:  Biochem Pharmacol       Date:  2012-01-11       Impact factor: 5.858

3.  Identification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia.

Authors:  Patrick K Campbell; Yang Zong; Shengping Yang; Sheng Zhou; Jeffrey E Rubnitz; Brian P Sorrentino
Journal:  Leuk Res       Date:  2011-10       Impact factor: 3.156

4.  Increased drug efflux along with midkine gene high expression in childhood B-lineage acute lymphoblastic leukemia cells.

Authors:  Ronghua Hu; Yan Yan; Qinghua Li; Yani Lin; Weina Jin; Huawen Li; Ying Lu; Tianxiang Pang
Journal:  Int J Hematol       Date:  2010-06-11       Impact factor: 2.490

Review 5.  The challenge of exploiting ABCG2 in the clinic.

Authors:  Robert W Robey; Caterina Ierano; Zhirong Zhan; Susan E Bates
Journal:  Curr Pharm Biotechnol       Date:  2011-04       Impact factor: 2.837

6.  Hypermethylation of ATP-binding cassette B1 (ABCB1) multidrug resistance 1 (MDR1) is associated with cisplatin resistance in the A549 lung adenocarcinoma cell line.

Authors:  Angui Li; Jianfei Song; Qi Lai; Bangqing Liu; Haiyong Wang; Yinhui Xu; Xiaoyan Feng; Xiaolin Sun; Zhenzong Du
Journal:  Int J Exp Pathol       Date:  2016-12-20       Impact factor: 1.925

Review 7.  Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities.

Authors:  Macus Tien Kuo
Journal:  Antioxid Redox Signal       Date:  2009-01       Impact factor: 8.401

8.  ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.

Authors:  Jo Ishizawa; Kensuke Kojima; Dhruv Chachad; Peter Ruvolo; Vivian Ruvolo; Rodrigo O Jacamo; Gautam Borthakur; Hong Mu; Zhihong Zeng; Yoko Tabe; Joshua E Allen; Zhiqiang Wang; Wencai Ma; Hans C Lee; Robert Orlowski; Dos D Sarbassov; Philip L Lorenzi; Xuelin Huang; Sattva S Neelapu; Timothy McDonnell; Roberto N Miranda; Michael Wang; Hagop Kantarjian; Marina Konopleva; R Eric Davis; Michael Andreeff
Journal:  Sci Signal       Date:  2016-02-16       Impact factor: 8.192

9.  MPT0B169, a novel tubulin inhibitor, induces apoptosis in taxol-resistant acute myeloid leukemia cells through mitochondrial dysfunction and Mcl-1 downregulation.

Authors:  Che-Chuan Wang; Hsinjin Eugene Liu; Yueh-Lun Lee; Yu-Wen Huang; Yi-Ju Chen; Jing-Ping Liou; Huei-Mei Huang
Journal:  Tumour Biol       Date:  2015-11-25

Review 10.  Cancer stem cell definitions and terminology: the devil is in the details.

Authors:  Peter Valent; Dominique Bonnet; Ruggero De Maria; Tsvee Lapidot; Mhairi Copland; Junia V Melo; Christine Chomienne; Fumihiko Ishikawa; Jan Jacob Schuringa; Giorgio Stassi; Brian Huntly; Harald Herrmann; Jean Soulier; Alexander Roesch; Gerrit Jan Schuurhuis; Stefan Wöhrer; Michel Arock; Johannes Zuber; Sabine Cerny-Reiterer; Hans E Johnsen; Michael Andreeff; Connie Eaves
Journal:  Nat Rev Cancer       Date:  2012-10-11       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.